Drug Trial Radar · NCT02576717
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Jan 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,494
Actual
Start
Oct 16, 2015
Primary completion
Jan 5, 2023
Study completion Jan 5, 2023
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Oct 15, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.
Conditions
- Multiple Sclerosis
Interventions
RPC1063Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Adverse Events (AEs)Time frame: From first dose to 90-days post last dose (an average of 65 months up to a max of 85 months)
- Number of Participants Experiencing Serious Adverse Events (SAEs)Time frame: From first dose to 90-days post last dose (an average of 65 months up to a max of 85 months)
- Number of Participants Experiencing Adverse Events (AEs) Leading to DiscontinuationTime frame: From first dose to 90-days post last dose (an average of 65 months up to a max of 85 months)
- Number of Participants Experiencing Adverse Events (AEs) Leading to WithdrawalTime frame: From first dose to 90-days post last dose (an average of 65 months up to a max of 85 months)
- Number of Participants Experiencing Adverse Events (AEs) of Special InterestTime frame: From first dose to 90-days post last dose (an average of 65 months up to a max of 85 months)
- Number of Participants With Abnormalities in Blood Absolute Lymphocyte Count (ALC)Time frame: From first dose up until last dose of study treatment (up to approximately 82 months)
- Number of Participants With Abnormalities in White Blood Cell Count (WBC)Time frame: From first dose up until last dose of study treatment (up to approximately 82 months)
- Number of Participants With Abnormalities in Blood Absolute Neutrophil Count (ANC)Time frame: From first dose up until last dose of study treatment (up to approximately 82 months)
- Number of Participants With Abnormalities in Specific Liver Function TestsTime frame: From first dose up until last dose of study treatment (up to approximately 82 months)
- Number of Participants With Electrocardiogram (ECG) Result AbnormalitiesTime frame: From first dose to 28-days post last dose (an average of 63 months up to a max of 83 months)
- Number of Participants With Clinically Relevant Abnormalities in Vital SignsTime frame: At baseline and 60 months after first dose of study therapy
- Number of Participants With Physical Examination AbnormalitiesTime frame: At baseline and every 12 months thereafter up until 84 months post first dose.
- Number of Participants Self-Identifying Suicidality by Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: At baseline and every 3 months thereafter up until 78 months post first dose.
- Number of Participants With Changes in Suicidality From Last Day on Treatment Per the Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: 1, 4, 7, 14, 21, 28, and 90 days post last dose.
- Change in Physician's Withdrawal Checklist (PWC-20) Total Score From Last Day on TreatmentTime frame: 1, 4, 7, 14, 21, and 90 days post last dose.
- Change in Hospital Anxiety and Depression Scale (HADS) Score From Last Day on TreatmentTime frame: 1, 4, 7, 14, 21, and 90 days post last dose.
- Changes in Epworth Sleepiness Scale (ESS) Score From Last Day on TreatmentTime frame: 1, 4, 7, 14, 21, and 90 days post last dose.
- Changes in Vital Sign Values From Last Day on TreatmentTime frame: 1, 4, 7, 14, 21, 28, and 90 days post last dose.
Locations
175 sites in 26 countries. Site status is shown where the registry gives one.
Local Institution - 115
Phoenix, Arizona
Local Institution - 118
Phoenix, Arizona
Local Institution - 110
Berkeley, California
Local Institution - 103
Fresno, California
Local Institution - 122
Long Beach, California
Local Institution - 112
Sacramento, California
Local Institution - 120
San Francisco, California
Local Institution - 114
Maitland, Florida
Local Institution - 123
Port Charlotte, Florida
Local Institution - 124
Sunrise, Florida
Local Institution - 147
Tampa, Florida
Local Institution - 137
Golden Valley, Minnesota
Local Institution - 170
Las Vegas, Nevada
Local Institution - 143
Raleigh, North Carolina
Local Institution - 107
Westerville, Ohio
Local Institution - 144
Knoxville, Tennessee
Local Institution - 138
Lubbock, Texas
Local Institution - 179
Round Rock, Texas
Local Institution - 141
Kirkland, Washington
Local Institution - 907
Grodno, Belarus
Local Institution - 904
Homyel, Belarus
Local Institution - 902
Minsk, Belarus
Local Institution - 901
Minsk, Belarus
Local Institution - 903
Minsk, Belarus
Local Institution - 905
Vitebsk, Belarus
Local Institution - 906
Vitebsk, Belarus
Local Institution - 256
Bruges, Belgium
Local Institution - 255
Brussels, Belgium
Local Institution - 252
Montegnée, Belgium
Local Institution - 913
Banja Luka, Bosnia and Herzegovina
Local Institution - 911
Sarajevo, Bosnia and Herzegovina
Local Institution - 453
Sofia, Bulgaria
Local Institution - 454
Sofia, Bulgaria
Local Institution - 452
Sofia, Bulgaria
Local Institution - 456
Sofia, Bulgaria
Local Institution - 457
Sofia, Bulgaria
Local Institution - 460
Sofia, Bulgaria
Local Institution - 455
Sofia, Bulgaria
Local Institution - 923
Osijek, Croatia
Local Institution - 921
Zagreb, Croatia
Showing 40 of 175 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.